AlphaVax is developing both Anti-Infective and Anti-Cancer Vaccines Incorporating Our New RNA Particle Vaccine Technology -- So as to Redefine Vaccines and Their Role in Medicine
About Us
The Company’s corporate partnering strategy is to out-license our proprietary alphavaccine technology for specific disease and/or antigen applications for commercialization.
Products
AlphaVax 's in-house focus is today on the commercial potential of its alphavaccine vector technology in cancer immunotherapy. External third-party partners are working on anti-infective vaccines.
Technology
The alphavaccine technology is based on AlphaVax’s proprietary RNA replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus.
AlphaVax, Inc. (AVX)
We are a privately-held, clinical-stage biopharmaceutical company, that has used its proprietary RNA particle alphavaccine vector platform technology to generate a portfolio of seven vaccine candidates for infectious disease prevention; cancer immunotherapy. and candidates for bio-defence applications .
Four alphavaccine candidates, targeting human cytomegalovirus, influenza A virus, prostate cancer and HIV-1, have been evaluated in five Phase 1 clinical trials. In parallel, AVX has focused in articular on various clinical trials with two additional vaccine candidates (one in breast cancer, two in GI cancers) in the development of immunotherapeutic vaccines for the treatment of cancers. its proprietary alphavaccine RNA particle technology, engage the patient’s immune system both to recognize and fight off various cancers.
Results from AVX’s first trial evaluating its CEA alphavaccine in patients with Stage IV colon cancer showed the vector technology was able to “break self-tolerance” with a reported trend for enhanced survival in patients with CEA-specific T cell responses.
As a follow-up, AVX has completed clinical trials in breast cancer and gastrointestinal cancers (in Stage III patients).